Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down before the market opened on Monday. The stock had previously closed at $14.88, but opened at $14.23. Ascentage Pharma Group International shares last traded at $14.07, with a volume of 429 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th. BTIG Research restated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Citizens Jmp began coverage on shares of Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective for the company. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 target price on the stock. Finally, William Blair began coverage on Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $43.90.

Ascentage Pharma Group International Trading Down 4.5%

The stock’s 50 day moving average is $15.85 and its two-hundred day moving average is $20.20. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.